Kornimate/medical-research-clean huggingface dataset:
safety of fmt using oral encapsulated prim-dj2727 in hiv

Conditions: HIV-1-infection

Summary: the purpose of this study is to determine whether oral fecal microbiota transplantation (fmt) is safe for people with human immunodeficiency virus (hiv) infection.


Eligibility criteria:
inclusion criteria: * hiv-1 infection, documented by any licensed hiv test * male subjects ≥ 18 years of age * identify as msm (men who have sex with men) * currently on continuous art for ≥24 weeks prior to study entry with no change in the art regimen within the 12 weeks prior to study * ability and willingness of the participating subject to sign the informed consent form * no plan to change art regimen for the study duration * screening cd4+ cell count \>350 cells/mm3 obtained within 45 days prior to study entry * hiv rna \< 20 copies/ml for ≥12 weeks (1 blip of \< 500 copies/ml will be permitted) * absolute neutrophil count ≥ 1000 cells/mm3 exclusion criteria: * initiation of art during acute/early hiv infection (within 6 months of hiv seroconversion) * co-infection with hepatitis b (positive hbsag or positive hbcab total with detectable hbv dna levels) or hepatitis c (positive hcv igg with detectable hcv rna levels) * use of antibiotics 60 days prior to the study entry * use of investigational therapies or vaccines 60 days prior to the study entry * serious illness requiring systemic treatment and/or hospitalization within 30 days prior to entry * cirrhosis, inflammatory bowel disease, total colectomy, colon or rectal anastomosis, bowel resection, or current colostomy * diabetes mellitus * any episode of acute or persistent diarrhea within 60 days prior to study entry * use of any of the following medications/products for more than 3 consecutive days within the 60 days prior to study entry: immunosuppressives, immune modulators, antineoplastic agents (except for topical agents for skin cancer), probiotics and prebiotics (supplements and products).
a study on the effection of potassium citrate extended-release tablets on urolithiasis formation or recurrence

Conditions: Urolithiasis

Summary: assess the efficacy and safety of potassium citrate extended-release tablets on urolithiasis formation or recurrence.

this study takes "rate of stone recurrence" as primary outcome measure, by random, blank control, and multicenter clinical trial design method, assess the efficacy and safety of potassium citrate extended-release tablets on urolithiasis formation or recurrence, provide evidence for drug re-registration, and observe its efficacy on urinary calculi such as renal tubular acidosis with calcium stone, and uric acid stones with or without calcium stone, urinary tract stone of effectiveness.

Eligibility criteria:
inclusion criteria: * patients with upper urinary tract calculi surgery and/or eswl within 3 months； * stone free or had residual stone fragments with a less than 4 mm diamete； * 18-70 years of age; the gender is not limited； * agree to take effective contraceptive measures during the study period, and female of childbearing age whose pregnancy test is negative； * subjects with no mental illness and language dysfunction, can understand the situation of the study and have signed informed consent. exclusion criteria: * patients with infectious stones, medical stones and urinary tract obstruction； * patients with hyperkalemia (k+\>5.5mmol/l) (or patients with factors or disease that can cause hyperkalemia), because the further increase in blood potassium can lead to cardiac arrest. these factors include disease or strenuous exercise, chronic renal failure, uncontrolled diabetes, acute dehydration, excessive, adrenal insufficiency, extensive tissue failure. patients who takes potassium sparing diuretics (such as triamterene, spironolactone, amiloride)； * patients with gastrointestinal disorders, such as peptic ulcer, severe vomiting, diarrhea, delayed gastric emptying, intestinal obstruction, etc.； * combined with cardiovascular, liver, kidney, hematopoietic system, such as severe primary disease, or known to affect the survival of serious diseases (such as cancer or aids), or patients with with disabilities mentally or legally； * patients with renal insufficiency (1.2 times the upper limit of the normal value of serum creatinine and urea nitrogen)； * the recent (within 6 months) with family planners； * allergic to this product； * to participate in other clinical trials in the past three months.
clinical trial of tumor cell-derived microparticles packaging chemotherapeutic drugs to treat malignant pleural effusion

Conditions: Malignant Pleural Effusion

Summary: the study is to investigate the anticancer effect and the related immunological mechanism of mtx-atmps in the treatment of malignant pleural effusion.

malignant pleural effusion(mpe) as a common complication of advanced lung cancer is lack of efficient treatments. the investigators have successfully produced tumor cell-derived microparticles packaging chemotherapy drugs and confirmed that this new integrative targeted biochemotherapy treatment could effectively restrain tumor growth at cellular and animal levels.this new method could control tumor growth in vivo effectively and induced pleural adhesion in the early clinical study. so the investigators attempt to explore the anticancer effect and related immune regulation mechanism of methotrexate-autologous tumor derived microparticles (mtx-atmps) in mpe treatment. the tumor cells in the malignant pleural effusion are prepared by screening, then mtx-atmps are made. participants enrolled are randomly assigned to experimental and control group, each of them is injected with the prepared drug once in two days until the malignant pleural effusion are disappeared or the treatment cycle has been six times. during or after the whole treatment, reactions to each treatment of the participants are carefully followed up.

Eligibility criteria:
inclusion criteria: 1. the diagnosis of lung cancer and malignant pleural effusion was confirmed by pathology and / or pleural fluid cytology; 2. the routine surgery or systemic radio/chemotherapy was ineffective, the mpe relapsed, or routine treatment therapy was given up by self-causes; 3. stable vital sign with kps(karnofsky performance status) index more than 60; 4. 18-70 years old; 5. normal haematopoietic function of bone marrow, no hemorrhagic tendency, blood routine test: hgb\>=100g/l, wbc\>4.0\*10\^9/l, plt\>80\*10\^9/l, serum alt, ast within 2 times upper limit of normal, bun within 1.5 time upper limit of normal, creatinine within normal range, normal ekg; 6. agreed to participate in the study and sign an informed consent; 7. without other severe comorbidities. exclusion criteria: 1. lactating or pregnant patients; 2. allergy to multiple drugs; 3. with other severe comorbidities or psychological diseases; 4. severe infection; 5. participation in other clinical trials within the recent three months.

Keywords: chemotherapy microparticle malignant pleural effusion
relationship between preoperative subcutaneous trochanteric fat thickness and postoperative infection risk

Conditions: Hip Infection

Summary: the effect of preoperative subcutaneous trochanteric fat thickness and trochanteric soft tissue thickness on postoperative infection risk in patients undergoing hemiarthroplasty for femoral neck fracture

obesity is a growing problem for healthcare systems and orthopaedic surgeons, with 29% of the adult population in the uk and 40% in the us affected by obesity. the most commonly used measure of obesity in healthcare is body mass index (bmi), and the world health organisation defines obesity as a bmi ≥ 30 kg/m2. much of the arthroplasty literature has also focused on the use of bmi as a measure of obesity. bmi-defined obesity is associated with an increased risk of perioperative complications (including infection and dislocation) in total hip arthroplasty. it has also been shown that there is a gradual increase in anaesthetic time, operative time and length of hospital stay as bmi increases in obese patients. bmi is an imperfect measure because it does not take into account age, sex, race, fat distribution or muscle mass. previous studies have shown that subcutaneous fat depth (fd) is an independent risk factor for wound infection in cervical and lumbar spine surgery and after laparotomy. it is not known whether increased subcutaneous fat and soft tissue mass are associated with an increased risk of complications after arthroplasty for femoral neck fractures. the aim of this study was to investigate whether preoperative measurement of subcutaneous adipose tissue by radiography and computed tomography (ct) and muscle thickness in the gluteus medius/minus, gluteus maximus, anterior and medial compartments by computed tomography (ct) in femoral neck fractures correlate with infection rates at postoperative follow-up. hypothesis: in patients with high body mass index (bmi) with femoral neck fractures, the investigators believe that the relationship between increased subcutaneous adipose tissue on radiographs and ct sections and wound infection is as effective as the relationship between increased muscle thickness in the gluteus medius/minimus, gluteus maximus, anterior and medial compartments measured on ct sections and wound infection.

Eligibility criteria:
inclusion criteria: * patients over 65 years of age * femoral neck fractures * female patients * patients undergoing hemiarthroplasty exclusion criteria: * patients younger than 65 years * male patients * patients with immunosuppressive conditions * intertrochanteric fractures * patients with revision surgery * pathological femoral neck fractures

Keywords: subcutaneous trochanteric fat thickness infection femoral neck fracture soft tissue thickness obesity hemiarthroplasty
effect of dexamethasone on duration of lower extremity blocks with bupivacaine in subjects having acl repair

Conditions: Duration of Pain Relief

Summary: anterior cruciate ligament reapair is a painful procedure. single shot femoral and sciatic nerve block only last 12-16 hrs. since dexamethasone prolongs brachial plexus block, using it in lower extremity blocks will prolong the analgesia to provide better outpatient pain relief after surgery at home.


Eligibility criteria:
inclusion criteria: * age 18-75, no contraindication to regional anesthesia exclusion criteria: * peripheral neuropathy

Keywords: anterior cruciate ligament block duration
anlotinib hydrochloride combined with capeox in the neoadjuvant treatment of locally advanced rectal cancer

Conditions: Neoadjuvant Treatment; Rectal Cancer; Anlotinib

Summary: prospectively investigate the effectiveness and safety of anlotinib hydrochloride combined with capeox in neoadjuvant treatment of patients with locally advanced rectal cancer.


Eligibility criteria:
inclusion criteria: 1. subjects voluntarily join the study and sign an informed consent form, have good compliance and cooperate with follow-up; 2. male or female patients between the ages of 18-75; 3. patients diagnosed as rectal adenocarcinoma by histology or cytology; 4. stage: locally advanced stage (t3-4n0m0 or t1-4n+m0); 5. evaluation of middle and low rectal cancer with the lower pole of the tumor less than 12 cm from the anal margin by mri; 6. have not received other anti-angiogenic drugs or chemotherapy drugs in the past; 7. ecog (eastern us cooperative oncology group) score: 0-1 points; 8. has sufficient organ and bone marrow function exclusion criteria: 1. other malignant tumors that have appeared or are currently suffering from within 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors \[ta (non-invasive tumor), tis (carcinoma in situ) ) and t1 (tumor infiltration basement membrane)\]; 2. a distant transfer occurs; 3. those who have multiple factors that affect oral medications (such as inability to swallow, chronic diarrhea, etc.); 4. accompanied by pleural effusion or ascites, causing respiratory syndrome (nci-ctc ae v5.0 grade ≥ 2 dyspnea); 5. patients with any severe and/or uncontrollable disease； 6. patients with gastrointestinal diseases with bleeding tendency (such as active gastrointestinal ulcers) or patients determined by the researcher to cause gastrointestinal bleeding, perforation or obstruction 7. patients whose imaging shows that the tumor has invaded the tissues around important blood vessels or the investigator judges that the tumor is likely to invade important blood vessels and cause fatal bleeding during the follow-up study; 8. received major surgical treatment, open biopsy or obvious traumatic injury within 28 days before grouping; 9. regardless of the severity, patients with any signs of bleeding or medical history; within 4 weeks before grouping, patients with any bleeding or bleeding events nci-ctc ae v5.0 grade ≥ 3, unhealed wounds, ulcers or fracture 10. those who have had arterial/venous thrombotic events within 6 months, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis and pulmonary embolism; 11. people with a history of psychotropic drug abuse and unable to quit or have mental disorders; 12. participated in other anti-tumor drug clinical trials within four weeks; 13. according to the judgment of the investigator, those with concomitant diseases that seriously endanger the safety of the patient or affect the completion of the study; 14. female patients who are pregnant or breastfeeding; 15. known hypersensitivity to any study drug.

Keywords: neoadjuvant treatment rectal cancer anlotinib
a pilot study for efficacy of cognitive and physical training in patients with mild cognitive impairment

Conditions: Patients With Mild Cognitive Impairment (MCI)

Summary: this is to find out the effectiveness of cognitive and physical function training for patients with mild cognitive impairment. it is for the prevention and treatment of dementia in the future. randomized, pilot study.


Eligibility criteria:
inclusion criteria: 1. men and women aged 60 or older 2. a person who falls within the abnormal range of the montreal cognitive assessment (moca) test 3. a person who can independently carry out daily life 4. if the subject or legal representative voluntarily decides to participate and agrees in writing to comply with the precautions after hearing and fully understanding the detailed explanation of this clinical study exclusion criteria: 1. a person diagnosed with alzheimer's dementia or other causes (stroke, brain tumor, cerebral palsy, dementia, parkinson's disease, etc.) 2. a person with unstable cardiovascular system, digestive system, respiratory system, endocrine system, etc. and poor general condition 3. patients who have participated in other treatment clinical studies or who have participated in other treatment clinical studies within the last 30 days 4. other cases where the researcher determines that participation in this clinical study is not appropriate
a safety study of brentuximab vedotin in participants with hiv

Conditions: Human Immunodeficiency Virus

Summary: this study will test brentuximab vedotin to see if it is safe for people with human immunodeficiency virus (hiv) who have low cd4+ and have received antiretroviral therapy (art) treatment. it will also see if brentuximab vedotin raises cd4+ counts. it will study the side effects of this drug as well. a side effect is anything a drug does to the body besides treating the disease. in this study participants will be assigned randomly to a group. participants will get either brentuximab vedotin or placebo. a placebo looks like the drug but does not contain any medicine in it. all participants will keep getting art during the study.


Eligibility criteria:
inclusion criteria: * hiv-1 seropositive with documentation of infection * immunological nonresponder, defined as: * has been on art with an hiv viral load \<50 copies/ml for at least 24 months * has a cd4+ t-cell lymphocyte count between 51 to 200 cells/µl * life expectancy of \>9 months. * participant is negative for hepatitis b, or if infected with hepatitis b, receiving anti-hepatitis b therapy * participants with a history of hepatitis c virus (hcv) are eligible if they have completed therapy for hcv and show sustained virologic remission (12 weeks or more) exclusion criteria: * any currently active aids-defining illness per category c conditions according to the cdc classification system for hiv infection, with the following exceptions: * limited cutaneous kaposi's sarcoma not currently requiring systemic therapy * wasting syndrome due to hiv or any other aids-defining illness for which no therapeutic treatment is required or the required treatment is not included in the list of prohibited medications * acute liver disease or any other active infection secondary to hiv requiring acute therapy * history of progressive multifocal leukoencephalopathy (pml) * prior clinical john cunningham virus (jcv) infection, history of jcv identified in cerebrospinal fluid, or presence of jcv antibodies at screening * cirrhosis secondary to any cause * any immunomodulating therapy (excluding premedication steroid) within 4 weeks prior to the screening visit * prior malignancy within 2 years other than cutaneous basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, anal intraepithelial neoplasia, or cutaneous kaposi's sarcoma

Keywords: hiv immunological nonresponder seattle genetics
effectiveness of glucosamine + chondroitin in osteoarthrosis

Conditions: Osteoarthrosis

Summary: this study objective is to check the non-inferiority of the 2 formulations produced by ems when compared with the same substances and pharmaceuticals forms of the product condroflex (zodiac), by promoting the relief of osteoarthrosis symptoms such as pain, stiffness and functional capacity that will be periodically measured by using the "visual analog scale" of pain (vas) and the questionnaire of lequesne.


Eligibility criteria:
inclusion criteria: * patients who agree with all aspects of the study and sign the informed consent; * patients of both sexes; * age above 30 years; * clinical and radiological diagnosis of osteoarthritis; * osteoarthritis in grades 1-2; * patients who are conducting medical treatment and that, for trial of investigator, is eligible for the study. exclusion criteria: * patients with a history of trauma clinically significant; * patients who underwent surgery on joints affected; * coexistence of diseases that might impede the successful conclusion of the trial (rheumatism and others); * pregnant patients and / or breastfeeding; * patients with phenylketonuria; * patients with clinical diagnosis of severe renal failure; * patients with clinical diagnosis of severe liver disease; * patients with clinical diagnosis of clotting disorders; * patients who are being treated with anti-aggregating and / or anticoagulants; * patients with sensitive components of the formula; * patients with emotional disorders that interfere with the capture of data; * patients who do not agree with the purposes of the study and did not sign the informed consent.
long-term effect of tms in primary progressive aphasia

Conditions: Primary Progressive Aphasia; Frontotemporal Dementia; Alzheimer Disease

Summary: there are very few treatments for neurodegenerative disorders, and the efficacy of these treatments is generally modest. recent studies have shown a short-term positive effect of non-invasive neuromodulation techniques such as transcranial magnetic stimulation (tms) in primary progressive aphasia (ppa). ppa is a clinical syndrome associated with alzheimer's disease and frontotemporal degeneration. the aim of this study is to compare the effect of tms and language therapy versus language therapy and sham tms in patients with ppa during 6 months. a prospective, randomized, controlled, double-blind and parallel clinical trial will be conducted. the changes in brain metabolism using fdg-pet, language, neuropsychiatric symptoms, and daily-living activities will be assessed. connectivity changes using electroencephalography will also be examined. in addition, a subgroup of patients will be assessed with multimodal mri (structural and functional), and blood biomarkers. as a result of this project, valuable information about the long-term efficacy of non-invasive brain stimulation in ppa will be obtained, as well as the mechanisms of the therapy and clinical and neuroimaging factors associated with therapy response.


Eligibility criteria:
inclusion criteria: * diagnosis of ppa (gorno-tempini et al. 2011 criteria supported by neuroimaging) * cdr * language is the most prominent symptom exclusion criteria: * clinical dementia rating scale \> 1 * history of epilepsy or epileptiform activity in eeg * another disorder causing aphasia * any contraindication for tms * pregnancy * medical disorder with a life expectancy of less than one year * malignancy in the last two years * alcohol or drug abuse * major psychiatric disorder * inability to communicate (mutism) * use of anticonvulsants, benzodiazepines, donepezil/galantamine/rivastigmine, memantine, antidepressants and neuroleptics is permitted if they are at stable doses in the last three months.

Keywords: brain stimulation transcranial magnetic stimulation
cardiovascular risk assessment in patients treated with caduet

Conditions: Hypertension

Summary: compare the reduction in framingham's predicted 10-year risk of a coronary event (6) in patients with hypertension and at least three other cardiovascular risk factors (including diabetic patients) seen in private practice and randomized to either caduet or usual care.


Eligibility criteria:
inclusion criteria: * 1.male or female, 18 years of age or over, 2.patient with hypertension and at least three other cv risk factors, 3.hypertension, treated or not, but not at the currently recommended goals (140/90 mmhg for most patients, 130/80 mmhg for patients with diabetes or nephropathy). in case of treated hypertension, patients should be on their current treatment for at least 4 weeks before randomisation, exclusion criteria: * 1. patient with a history of coronary heart disease, 2.patients with a history of familial hypercholesterolemia, 3.patient with malignant htn, 4.non-essential hypertension, 5.known hypersensitivity to dihydropyridines, 6.patients already receiving a dihydropyridine, 7.known hypersensitivity to hmg-coa-reductase inhibitors, 8.patients currently receiving or who has received a hmg-coa-reductase within the 3 months prior to selection, 9.patients currently receiving or who has received a fibric acid, resins, ezetimibe, nicotinic acid and all other drug which is known to affect lipid levels, within 6 weeks prior to selection,
randomized control trial of sleeve gastrectomy with tirzepatide in maximizing weight loss

Conditions: Obesity and Obesity-related Medical Conditions

Summary: this study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.


Eligibility criteria:
inclusion criteria: * adult 18 to 65 years of age * body mass index \>35 with comorbidity of type 2 diabetes and/or hypertension and/or hyperlipidemia and/or obstructive sleep apnea or body mass index \>40 with or without comorbidity * undergoing primary sleeve gastrectomy exclusion criteria: * prior metabolic and bariatric surgery * prior use of glp-1 agonist * prior history of pancreatitis * personal/family history of medullary thyroid cancer or men type 2 * secondary cause of obesity * any eating disorder * pregnancy/lactation * history of acute coronary syndrome or myocardial infarction * history of stroke * hepatic dysfunction: ast/alt \>3 uln * renal dysfunction egfr\<45ml/min/1.73m2 * active malignancy * history of diabetic retinopathy * history of gastroparesis